Related Experiment Video
Updated: May 18, 2026
14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Strategies for p53 reactivation in human sarcoma
Ted R Hupp1, Richard L Hayward, Borek Vojtesek
1Institute of Genetics and Molecular Medicine, University of Edinburgh, UK. ted.hupp@ed.ac.uk
Cancer Cell
|September 15, 2012
Summary
Emerging cancer therapies integrate genomic and proteomic data for target selection. Researchers found the mesenchymal protein Twist1 inhibits p53, offering a new therapeutic target for human sarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Cancer therapeutic strategies increasingly leverage multi-omics data, integrating genomic and proteomic information for precise target identification.
- The tumor suppressor protein p53 plays a critical role in preventing cancer, but its function is often compromised in malignant cells.
Discussion:
- This study investigates the interplay between the mesenchymal protein Twist1 and the p53 pathway in cancer.
- The research demonstrates that Twist1 actively suppresses p53 activity, highlighting a novel mechanism of oncogenesis.
Key Insights:
- The mesenchymal protein Twist1 directly inhibits the tumor suppressor p53.
- Reactivation of p53 presents a promising therapeutic strategy for human sarcoma.
Outlook:
- Targeting the Twist1-p53 interaction could lead to novel therapeutic approaches for sarcoma.
- Further research into Twist1's role in other cancers may reveal broader therapeutic applications.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:36DNA Damage Can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
02:36DNA Damage can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...